| Drug Name: | Tolazamide (1156-19-0) |
|---|---|
| PubChem ID: | 5503 |
| SMILES: | CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2 |
| InchiKey: | OUDSBRTVNLOZBN-UHFFFAOYSA-N |
| Therapeutic Category: | Hypoglycemic Agents |
| Molecular Weight (dalton) | : | 311.407 |
| LogP | : | 1.77392 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 78.51 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Tolazamide-Induced Wernicke Encephalopathy | Transketolase (P29401) | Transketolase abnormality in tolazamide-induced Wernicke#s encephalopathy [ ADR Type 3 ] | Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category